COMPASS PATHWAYS PLC

CMPSNASDAQ

🏆 #2074 by market capEarnings Nov 2US Equity

$12.96▼ $0.27 (−2.08%)

After hours · at close

🔔

Track CMPS

Get earnings, price moves & breaking news on Telegram

Track

24h▼ 2.1%

7d▼ 12.3%

14d▼ 6.2%

30d▼ 5.5%

ytd▲ 87.8%

1y▲ 121.2%

🏦Market Cap

$1.75B

Small Cap

📈Revenue Growth (YoY)

—

📊Gross Margin

—

💵FCF Margin

—

⚖️P/S Ratio

—

Otter Score

Weak

Trading Snapshot

Day Range: $12.91 – $13.21
52-Week Range: $4.88 – $15.87
Volume: $2.53B
Avg Volume: $2.39B
Shares Outstanding: 134.9M
Next Earnings: Dec 2, 2026

Fundamentals Snapshot

Annual Revenue: $129M
Last Q Revenue: $34M
P/E Ratio: —
P/S Ratio: —
EPS (TTM): $-3.47
Dividend Yield: —
Dilution (1yr): +36.8%

Why Investors Own CMPS

✓High-growth profile — revenue up +2.3% YoY with expanding US Equity exposure.
✓Healthy economics — 25% gross margin and 4% free-cash-flow margin.
✓New products and segments could unlock additional revenue streams.

⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

COMPASS PATHWAYS PLC

CMPS

Financial Trends

Revenue

$0▲ +0.0% YoY

Operating Income

−$179M▲ +0.5% YoY

Free Cash Flow

−$157M▲ +31.9% YoY

Shares Outstanding

93.6M▲ +36.8% YoY

Net Cash

$115M▼ −$18M YoY

StockOtter · stockotter.space

About COMPASS PATHWAYS PLC

COMPASS Pathways plc is a mental healthcare company with a primary presence in the United Kingdom and the United States. Established in 2020 and headquartered in London, UK, the firm focuses on developing novel treatments. Its key product is COMP360, an investigational psilocybin therapy. This therapy has advanced through Phase IIb clinical trials for treatment-resistant depression and is currently undergoing Phase II trials for post-traumatic stress disorder. The company previously operated under the name COMPASS Rx Limited before rebranding to COMPASS Pathways plc in August 2020.

🦦